[Federal Register Volume 74, Number 81 (Wednesday, April 29, 2009)]
[Notices]
[Pages 19594-19595]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-9782]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application

    Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to 
issuing a registration under this Section to a bulk manufacturer of a 
controlled substance in schedule I or II, and prior to issuing a 
regulation under 21 U.S.C. 952(a)(2) authorizing the importation of 
such a substance, provide manufacturers holding registrations for the 
bulk manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with Title 21 Code of Federal Regulations 
Sec.  1301.34(a), this is notice that on February 20, 2009, Meridian 
Medical Technologies, 2555 Hermelin Drive, St. Louis, Missouri 63144, 
made application by renewal to the Drug Enforcement Administration 
(DEA) to be registered as an importer of Morphine (9300), a basic class 
of controlled substance listed in schedule II.
    The company plans to import products for research experimentation 
or clinical use and analytical testing.
    Any bulk manufacturer who is presently, or is applying to be, 
registered with DEA to manufacture such basic class of controlled 
substance may file comments or objections to the issuance of the 
proposed registration and may, at the same time, file a written request 
for a hearing on such application pursuant to 21 CFR 1301.43 and in 
such form as prescribed by 21 CFR 1316.47.
    Any such comments or objections being sent via regular mail should 
be addressed, in quintuplicate, to the Drug Enforcement Administration, 
Office of Diversion Control, Federal Register Representative (ODL), 
8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed 
no later than May 29, 2009.
    This procedure is to be conducted simultaneously with, and 
independent of, the procedures described in 21 CFR 1301.34(b), (c), 
(d), (e), and (f). As noted in a previous notice published in the 
Federal Register on September 23, 1975 (40 FR 43745-46), all applicants 
for registration to import a basic class of any controlled substance 
listed in schedule I or II are, and will continue to be, required to 
demonstrate to the Deputy Assistant Administrator, Office of Diversion 
Control, Drug Enforcement Administration, that the requirements for 
such registration pursuant to 21 U.S.C. 958(a), 21 USC Sec.  823(a), 
and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.


[[Page 19595]]


    Dated: April 17, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E9-9782 Filed 4-28-09; 8:45 am]
BILLING CODE 4410-09-P